GLP-1 Prescriptions in Young Children Jump 310-Fold, Mostly Off-Label

What Happened

Prescriptions of GLP-1 receptor agonists for US children ages 8 to 11 with obesity rose 310-fold between 2019 and mid-2026 — from 0.03% to 9.3% of that group — according to a peer-reviewed study published in the journal Pediatrics and led by Dr. Babak J. Orandi of NYU Grossman School of Medicine. The team analyzed electronic health records covering more than 3.5 million children over seven and a half years.

The striking detail: no leading weight-loss GLP-1 formulation is FDA-approved for chronic weight management below age 12. The agents tracked — semaglutide, liraglutide, and tirzepatide — were prescribed to this age group almost entirely off-label, even though professional guidelines allow clinicians to consider them from age 8 in high-risk cases.

In total, 20,282 children ages 8 to 11 received a GLP-1 prescription during the study window, with semaglutide the most common first agent. Roughly 20% of US children live with obesity, defined as a BMI at or above the 95th percentile for age and sex.

Who Is Affected

The data show prescribing concentrated among the highest-risk children rather than spread across the pediatric population:

• 93.7% of children prescribed a GLP-1 had severe obesity (BMI above 120% of the 95th percentile for age and sex)
• 65.2% had at least one obesity-related comorbidity — high cholesterol, high blood pressure, or sleep apnea — versus 19.6% of non-users
• Roughly a quarter were prediabetic
• Girls were more likely than boys to receive the prescriptions
• Children in upper-income communities were 55% more likely to be prescribed a GLP-1, a gap the authors warn could deepen inequities in pediatric obesity care

Timeline

• 2019 — GLP-1 weight-loss prescribing in ages 8-11 sits at 0.03%; FDA approval for weight management stops at age 12
• 2022-2024 — adult demand for the drug class surges, and pediatric uptake quietly follows
• September 2026 — the Pediatrics study documents the 310-fold rise through June 2026
• November 2026 — results from a large semaglutide trial in children as young as 6 are expected to be presented at a medical conference, potentially reshaping the approval landscape

What This Means for Researchers

For the research community, this is the first national overview of GLP-1 use in young children. It confirms that clinicians are mostly reserving the drugs for children at greatest cardiometabolic risk — but it also shows how quickly off-label adoption can scale once a drug class becomes culturally dominant. The income-linked prescribing gap raises coverage-policy and equity questions that will grow sharper as trials in younger children mature.

The trend also signals that GLP-1 demand keeps outrunning the regulated supply chain — with predictable consequences for the unregulated market, where counterfeit injectables remain a persistent enforcement priority.

How to Verify Your Peptides

If you source GLP-1 compounds for research, independent verification is non-negotiable:

• Learn how lab verification works
• Understand the difference between HPLC and LC-MS analysis
• Review what identity, purity, and fill-weight testing confirms
• Choose a trusted third-party testing lab

Safe Alternatives

• Compare supplier reputations in our vendor directory before ordering anything
• Read the compound profiles for semaglutide, tirzepatide, and liraglutide

Sources

Peer-reviewed research published in Pediatrics (September 2026); institutional announcements from NYU Langone Health; regulatory announcements; industry reports.